Sealantium Medical News
2 articles
growth-positive
Sealantium Medical announces completion of its phase I/II clinical study - Sealantium
Sealantium Medical has completed the enrollment of 32 patients for its Phase I/II clinical study of its flagship product, sFilm-FS, in the EU and the U.S. The study is comparing the safety and efficacy of sFilm-FS against TachoSil, the market-leading product for controlling liver bleeding. Interim data suggests that sFilm-FS is safe and effective, with final data expected in 3Q23. Pivotal Phase III studies are expected to start in 4Q23.
Investment
growth-positive
Sealantium Medical retains Biotech Alliances International to Lead Series B $10 Million Capital Raise
Biotech Alliances International will serve as the lead investment banker to Sealantium Medical for its $10 million Series B capital raise. The funding will be used to complete Phase III study, manufacturing scale-up, and US/EU regulatory approval for Sealantium Medicals novel product, sFilm-FS™. The product is a bio-compatible bio-absorbable, polymeric film embedded with lyophilized human fibrinogen and human thrombin, offering a state-of-the-art solution to unmet surgical needs. Sealantium Medical has already completed safety and efficacy studies in rodents and pigs and has received the Seal of Excellence from the European Commission. Human studies will begin after FDA approval. Biotech Alliances International will introduce Sealantium Medical to international investors at a healthcare conference in San Francisco.
Investment
